- Home
- EHC vs EXAS Comparison
EHC vs EXAS Comparison
Compare EHC & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHC
- EXAS
- Stock Information
- Founded
- EHC 1983
- EXAS 1995
- Country
- EHC United States
- EXAS United States
- Employees
- EHC N/A
- EXAS N/A
- Industry
- EHC Hospital/Nursing Management
- EXAS Medical Specialities
- Sector
- EHC Health Care
- EXAS Health Care
- Exchange
- EHC Nasdaq
- EXAS Nasdaq
- Market Cap
- EHC 12.3B
- EXAS 10.7B
- IPO Year
- EHC 1986
- EXAS N/A
- Fundamental
- Price
- EHC $118.48
- EXAS $51.91
- Analyst Decision
- EHC Strong Buy
- EXAS Strong Buy
- Analyst Count
- EHC 8
- EXAS 20
- Target Price
- EHC $123.38
- EXAS $70.26
- AVG Volume (30 Days)
- EHC 749.9K
- EXAS 2.8M
- Earning Date
- EHC 08-04-2025
- EXAS 07-30-2025
- Dividend Yield
- EHC 0.58%
- EXAS N/A
- EPS Growth
- EHC 30.58
- EXAS N/A
- EPS
- EHC 4.84
- EXAS N/A
- Revenue
- EHC $5,512,600,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- EHC $10.73
- EXAS $14.58
- Revenue Next Year
- EHC $8.61
- EXAS $12.75
- P/E Ratio
- EHC $24.36
- EXAS N/A
- Revenue Growth
- EHC 11.21
- EXAS 11.57
- 52 Week Low
- EHC $82.74
- EXAS $39.97
- 52 Week High
- EHC $123.13
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- EHC 46.44
- EXAS 44.34
- Support Level
- EHC $116.39
- EXAS $52.00
- Resistance Level
- EHC $120.35
- EXAS $55.90
- Average True Range (ATR)
- EHC 1.93
- EXAS 2.31
- MACD
- EHC -0.50
- EXAS -0.04
- Stochastic Oscillator
- EHC 31.54
- EXAS 24.90
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.